Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. - Wikidata - wikimedia - TriplyDB

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

http://www.wikidata.org/entity/Q44087722

about

Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!Aldosterone synthase inhibition in humans Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure 30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development.The role of aldosteronism in causing obesity-related cardiovascular risk.Interfering with mineralocorticoid receptor activation: the past, present, and future New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.Eplerenone--a novel selective aldosterone blocker.Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome Aldosterone receptor antagonists: focus on eplerenone.Changes in the perceived epidemiology of primary hyperaldosteronism Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?Novel pharmacological treatments for heart failure.Emerging drugs in the management of hypertension.Aldosterone receptor antagonists: biology and novel therapeutical applications.Role of the selective aldosterone receptor blockers in arterial hypertension.Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure.The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.Novel antihypertensive agents.Use of aldosterone antagonists in resistant hypertension.Aldosterone blockade in cardiovascular disease.The use of aldosterone receptor blockers in the treatment of hypertension.Eplerenone in hypertension.Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.Resistant or difficult-to-treat hypertension.The pharmacological treatment of primary aldosteronism.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure Does eplerenone have a future in the management of hypertension in Europe?Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.Renal denervation in hypertensive patients not on blood pressure lowering drugs.Aldosterone synthase inhibitors in hypertension: current status and future possibilities.Review article: eplerenone: an underused medication?Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.

P2860

Q24531965-8AFD04B0-F05C-403E-9542-99E0BB1AEB00 Q24604026-8C0F5376-6A56-4410-9AEF-2EE6DFCBD881 Q26776149-47639813-5342-4756-8D46-BBACE787B285 Q27016157-44F0C9BC-8FC0-4A67-8357-E2EC03B28353 Q28066549-DC024C32-C7A0-4C55-82A1-ADEE4314E8E1 Q33846431-F0535A15-0850-4DB2-84D1-F20EF3020D20 Q33995992-5669C205-409C-488D-B94F-6AED62739BD6 Q34019947-B436FD5D-21D0-45B0-9DD9-2D29DE1A41FF Q34384580-F3A47773-E37C-43FC-8FF5-62010F4602C7 Q34874363-F45AEE4A-C990-4100-B2F9-40DD3451A8D0 Q35027295-0BCC450F-6E9A-4EBD-8C0D-C61D3A114181 Q35080685-3F8796F6-17AF-4F1D-9E2E-C17C6FD3CA1B Q35151575-65384B3E-1689-4820-92B5-22DF29376B89 Q35207607-3DFF8557-D2D6-4863-9EDF-1A97567AF94A Q35570949-23FA2D72-C623-4AC8-A77F-A7F9AF3DC913 Q35602652-D37275B6-0995-4CD5-93F7-6E2E698F2CE7 Q35605655-45AE4EE2-0FDA-4FBD-AEE8-F15858A42116 Q35770241-7DDD7441-CBB7-4603-9A23-B1373991534B Q35820248-D075A100-99C0-4CD5-A773-B7ABC452E7F3 Q35834925-4DDD4D52-6A92-423A-8ECD-B2853E97212A Q35842537-5A889301-837F-4D48-ACF2-18E00AE77105 Q35861997-54D76B28-0C67-42A1-9390-913D0B03B3D0 Q35887602-DCD81413-6EC0-422B-8599-4F250E8BBDE9 Q35945724-8A9DDCE8-7495-4084-B1A3-90A1DC6F4954 Q35967354-32C8586B-8BE5-4616-BA97-F0ABA8590615 Q35992464-BCD6E0A2-A813-4E24-82F2-82F4DF27E065 Q36124918-1A64E877-D494-4232-9D54-428A6E1FF79C Q36191021-EC76BAF2-CF0B-433C-83C2-CF4AC17611C1 Q36416109-491ABDDF-B352-4DCB-A1D3-94DD6D522BFA Q36428495-9F7FC357-9362-425B-AC64-C2267099FAC9 Q36437145-30F32B9C-E570-4EAF-A745-96BA6EC74714 Q36448508-C4B99A77-279B-4F9D-B745-E929313A685E Q36567077-0B843220-1E08-4E9A-A84D-0FA4B10D626D Q36568473-45C520D1-8546-46C6-8A4E-D5F61304DCD6 Q37000764-2AB8C528-5F92-4DC3-96A7-53E016376BE2 Q37184474-7B301BE8-2AD5-4634-9389-A1B027FF23E4 Q37594892-09A13650-30C5-44C5-BA8A-3B7426BCB4AD Q37793666-788C8DB5-BF43-4EAB-8218-2DE79F3FF775 Q37897992-DD73FAA5-772D-4471-BC37-1429407EA91F Q37928127-F532E09B-45B6-4894-9770-0A2773F1185A

P2860

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

http://www.wikidata.org/entity/Q44087722

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

@en

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

@nl

type

label

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

@en

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

@nl

prefLabel

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

@en

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

@nl

P1433

Q44087722-30FE85F8-D160-4BBC-962D-E7E025F375B9

P1476

Q44087722-930B4AE5-95A7-4AEE-9662-2478D6BA2980

P2093

Q44087722-125FDC01-50CE-4237-9762-2BD701D67695

Q44087722-42424CDD-1276-4693-B79D-FA3A69E58E93

Q44087722-6AFB1387-8FF5-4782-8CB6-7FD34B312819

Q44087722-E641DD0E-09D2-4CA1-9200-EA0817D23BCC

P2860

Q44087722-0E24E785-CE14-42EE-BD5F-C6988C649794

Q44087722-2403D82E-D3F8-4CCD-A6D4-7050A7EF9999

Q44087722-68A26E5B-8EF6-423D-8882-D5912572C1B9

Q44087722-9189DC87-FF33-4EB1-9297-3B4801D14978

Q44087722-AF40EFD6-1B27-4DD5-8281-8A5229F0B58D

Q44087722-D35FD84D-5941-4699-BAB5-6A8C65059878

Q44087722-E3392591-6063-4C6A-B4AF-4853A2934426

Q44087722-E51D099E-D550-41D9-B9C5-0AE0DA8F4A82

Q44087722-EB096261-0F99-4951-A9F2-75E8A4866E1C

P304

Q44087722-0E179148-A513-41FE-81D5-CBA24C6F0ECD

P31

Q44087722-AE7E3B69-5643-4645-9464-5459AB1F7E16

P356

Q44087722-FE0E513B-4A2D-4D7C-9AEF-E80EA4601BD0

P433

Q44087722-441CC034-2781-467E-88A9-670789BD6D79

P478

Q44087722-27C19C75-9B2F-4F21-8E0A-260D39E4BF4C

P577

Q44087722-9403A37D-2C4B-43D2-8F38-381DFECD0CBB

P698

Q44087722-28026E04-BE68-4885-8D49-556C8DA6879F

P356

S0895-7061(02)02957-6

P1433

American Journal of Hypertension

P1476

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

@en

P2093

Barbara Roniker

http://www.w3.org/2001/XMLSchema#string

Myron H Weinberger

http://www.w3.org/2001/XMLSchema#string

Robert J Weiss

http://www.w3.org/2001/XMLSchema#string

Scott L Krause

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.

Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension.

Aldosterone and antialdosterone therapy in congestive heart failure.

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure.

Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal.

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Efficacy and tolerance of spironolactone in essential hypertension.

P304

709-716

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0895-7061(02)02957-6

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12160194

http://www.w3.org/2001/XMLSchema#string